Literature DB >> 3221740

Interaction of aminoglycoside antibiotics and calcium channel blockers at the neuromuscular junctions.

A G Paradelis1, C J Triantaphyllidis, M Mironidou, L G Crassaris, D N Karachalios, M M Giala.   

Abstract

Aminoglycoside antibiotics (mmol.l-1) gentamicin (0.74), streptomycin (1.02), netilmicin (1.24), amikacin (2.23), sisomicin (2.74), dactimicin (2.75), kanamycin (3.43), kanendomycin (3.45), tobramycin (3.53) and dibekacin (4.35) produce a complete neuromuscular blockade at the isolated phrenic nerve-hemidiaphragm preparation of the rat, which is only reversed by calcium chloride. On the other hand, verapamil (2.04 mmol.l-1), a calcium channel blocker, also produces a complete neuromuscular blockade at the above preparation which is reversed by calcium chloride. Aminoglycoside antibiotics are potentially capable of interacting with verapamil and produce a complete neuromuscular blockade at concentrations significantly reduced. The neuromuscular blockade which is produced by the concurrent administration of the aminoglycoside antibiotics and verapamil is obtained with the usual therapeutic blood concentrations of the individual agents. Furthermore, the neuromuscular blockade which is produced during verapamil-aminoglycoside antibiotics interactions is completely reversed after calcium chloride administration. The mechanism by which aminoglycoside antibiotics and verapamil produce neuromuscular blockade must be the same. Both classes of drugs interfere with calcium ions movements through the calcium channels of the membrane of the motor nerve-endings inhibiting acetylcholine release at the synaptic cleft. The interaction of aminoglycoside antibiotics and calcium channel blockers is of clinical significance because when these agents are given concurrently during the perioperative period they may lead to respiratory depression or prolonged apnoea. These respiratory disturbances can be managed by slow intravenous infusion of 50 to 200 mg of calcium gluconate.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3221740

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  7 in total

1.  Aminoglycoside therapy: current and prospective uses.

Authors:  J E Leggett
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  New developments in aminoglycoside therapy and ototoxicity.

Authors:  Jing Xie; Andra E Talaska; Jochen Schacht
Journal:  Hear Res       Date:  2011-05-27       Impact factor: 3.208

Review 4.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

5.  Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021.

Authors:  Agam K Rao; Jeremy Sobel; Kevin Chatham-Stephens; Carolina Luquez
Journal:  MMWR Recomm Rep       Date:  2021-05-07

6.  Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA.

Authors:  Megan M Vucovich; Robert B Cotton; Elaine L Shelton; Jeremy A Goettel; Noah J Ehinger; Stanley D Poole; Naoko Brown; James L Wynn; Bibhash C Paria; James C Slaughter; Reese H Clark; Mario A Rojas; Jeff Reese
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-03       Impact factor: 4.733

7.  Adverse effects of polymyxin B administration to healthy horses.

Authors:  Julia N van Spijk; Katrin Beckmann; Meret Wehrli Eser; Martina Boxler; Martina Stirn; Thea Rhyner; Dana Kaelin; Lanja Saleh; Angelika Schoster
Journal:  J Vet Intern Med       Date:  2022-07-07       Impact factor: 3.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.